Eiger BioPharmaceuticals

Drug development orphan diseases


HBM contact: Dr Ivo Staijen, Dr Emil Bujak

Company status: public

Eiger is a clinical-stage company with four programs addressing orphan diseases with a high unmet medical need. Lonafarnib, a Phase 2 stage farnesyl inhibitor is being developed for HDV, the deadliest form of viral hepatitis. Other programs include therapies for hyperinsulinemic hypoglycemia following bariatric surgery, PAH and lymphedema. 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171